ZIVO Bioscience, Inc.
Income Statement
| Line Item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.6K | $53.4K | $0 | $90.0K | $31.5K | $0 | $35.7K | $11.8K |
| Cost of Revenue | $44.3K | $35.5K | $0 | $63.0K | $22.1K | $0 | $23.2K | $7.7K |
| Gross Profit | $21.3K | $17.9K | $0 | $27.0K | $9.5K | $0 | $12.5K | $4.1K |
| Gross Margin | 32.4% | 33.6% | — | 30.0% | 30.0% | — | 35.0% | 35.0% |
| Operating Expenses | ||||||||
| Research & Development | $203.4K | $479.7K | $2.8M | $243.5K | $326.4K | $2.3M | $312.8K | $312.5K |
| SG&A Expense | $836.2K | $1.2M | $1.4M | $1.4M | $1.9M | $6.0M | $975.6K | $1.6M |
| Operating Income | $-1.0M | $-1.6M | $-4.2M | $-1.6M | $-2.3M | $-8.2M | $-1.3M | $-1.9M |
| Operating Margin | -1,551.8% | -3,057.8% | — | -1,773.8% | -7,174.7% | — | -3,571.8% | -16,072.7% |
| Interest Expense | $13.0K | $7.4K | $2.4K | — | $8.6K | $6.8K | $2.6K | $-43.7K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | $0 | — |
| Net Income | $-1.0M | $-1.6M | $-4.2M | $-1.6M | $-2.3M | $-8.2M | $-1.3M | $-1.9M |
| Net Margin | -1,574.2% | -3,071.6% | — | -1,779.3% | -7,201.9% | — | -3,579.2% | -16,174.1% |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | $-0.27 | $-0.43 | $-1.12 | $-0.31 | $-0.67 | $-2.78 | $-0.47 | — |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | 2.4M |
| Shares Outstanding (Diluted) | 3.8M | 3.8M | 3.8M | 3.2M | 3.4M | 3.0M | 2.7M | 2.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |